Itabashi-ku
Itabashi-ku
Itabashi-ku, Tokyo, Japan35 results · Page 1 of 2
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity | Arterial Occlusive Diseases, Body Weight, Nutritional and Metabolic Diseases, Overweight, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, arteriosclerosis disorder, atherosclerosis, atherosclerotic cardiovascular disease, cardiovascular disorder, nutritional disorder, obesity disorder, overnutrition, vascular disorder | Recruiting | Phase 3 | 2026-10-08 | NCT07037433 | |
| A Study to Investigate GB-0895 Adjunctive Therapy in Adults and Adolescents With Severe Uncontrolled Asthma (SOLAIRIA-2) | Hypersensitivity, Immediate, Respiratory Hypersensitivity, asthma, bronchial disorder, immune system disorder, lung disorder, obstructive lung disease, respiratory system disorder | Recruiting | Phase 3 | 2026-10-07 | NCT07359846 | |
| Characterization And Clinical Outcomes of AA Patients Treated With Ritlecitinib | Skin and Connective Tissue Diseases, alopecia, alopecia areata, disorder of pilosebaceous unit, hypotrichosis, skin disorder | Active, not recruiting | Not stated | 2026-10-06 | NCT06531109 | |
| 24 Weeks Double-blind Randomized Placebo-controlled Trial to Evaluate Efficacy, PK, Safety of LOU064 in Adolescents (12 - <18) With CSU and Inadequate Response to H1-antihistamine Followed by Optional 3 Years Open-label Extension and an Optional 3 Years Safety Long-term Treatment-free Follow-up | Chronic Disease, Chronic Spontaneous Urticaria, Disease Attributes, Hypersensitivity, Immediate, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Skin and Connective Tissue Diseases, chronic urticaria, immune system disorder, skin disorder, skin vascular disease, urticaria | Active, not recruiting | Phase 3 | 2026-10-02 | NCT05677451 | |
| Phase 3 Extension Study to Evaluate Long-term Safety of Ianalumab in Participants With Systemic Lupus Erythematosus (SIRIUS-SLE Extension). | Skin and Connective Tissue Diseases, autoimmune disease, connective tissue disorder, immune system disorder, systemic lupus erythematosus | Recruiting | Phase 3 | 2026-10-01 | NCT06133972 | |
| A Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia | Cytopenia, Hemic and Lymphatic Diseases, Hemorrhage, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Purpura, Thrombocytopenic, Idiopathic, Signs and Symptoms, Skin Manifestations, autoimmune disease, blood coagulation disease, blood platelet disease, hematologic disorder, hemorrhagic disease, immune system disorder, purpura, thrombocytopenia, thrombocytopenic purpura, thrombotic microangiopathy | Recruiting | Phase 3 | 2026-09-18 | NCT06722235 | |
| A Study of Efficacy and Safety of Ianalumab in Previously Treated Patients With Warm Autoimmune Hemolytic Anemia | Warm Autoimmune Hemolytic Anemia (wAIHA) | Active, not recruiting | Phase 3 | 2026-09-11 | NCT05648968 | |
| A Study to Determine the Efficacy and Safety of Deucravacitinib Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Are Naïve to Biologic Disease Modifying Anti-rheumatic Drugs or Had Previously Received TNFα Inhibitor Treatment | Skin Diseases, Papulosquamous, Skin and Connective Tissue Diseases, Spondylarthritis, Spondylarthropathies, arthritic joint disease, arthropathy, bone disorder, musculoskeletal system disorder, psoriasis, psoriatic arthritis, skin disorder, spondylitis, vertebral column disorder | Active, not recruiting | Phase 3 | 2026-09-11 | NCT04908189 | |
| Specified Drug-use Surveillance of Fabhalta Capsules | Hemic and Lymphatic Diseases, Hemoglobinuria, Paroxysmal, anemia, bone marrow disorder, hematologic disorder, hemolytic anemia, myelodysplastic syndrome, paroxysmal nocturnal hemoglobinuria | Active, not recruiting | Not stated | 2026-09-10 | NCT06606314 | |
| A Long-Term Study of Zasocitinib in Children and Teenagers With Plaque Psoriasis | Plaque Psoriasis | Recruiting | Phase 3 | 2026-09-09 | NCT07250802 | |
| A Follow-up Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia | Cytopenia, Hemic and Lymphatic Diseases, Hemorrhage, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Purpura, Thrombocytopenic, Idiopathic, Signs and Symptoms, Skin Manifestations, autoimmune disease, blood coagulation disease, blood platelet disease, hematologic disorder, hemorrhagic disease, immune system disorder, purpura, thrombocytopenia, thrombocytopenic purpura, thrombotic microangiopathy | Recruiting | Phase 3 | 2026-09-09 | NCT06948318 | |
| An Open Label Extension (OLE) Study (Following Completion of CTQJ230A12301) to Evaluate Long-term Safety and Tolerability of Pelacarsen (TQJ230) | Infarction, Necrosis, Pathologic Processes, Pathological Conditions, Signs and Symptoms, brain disorder, cardiovascular disorder, central nervous system disorder, cerebrovascular disorder, heart disorder, ischemic disease, myocardial infarction, myocardial ischemia, nervous system disorder, stroke disorder, vascular disorder | Recruiting | Phase 3 | 2026-09-04 | NCT07517263 | |
| Study of ONO-4578 With and Without ONO-4538 in Subjects Advanced or Metastatic Solid Tumors | Advanced or Metastatic Solid Tumors | Active, not recruiting | Phase 1 | 2026-09-04 | NCT03155061 | |
| Phase 3 Study to Evaluate Two Regimens of Ianalumab on Top of Standard-of-care Therapy in Patients With Systemic Lupus Erythematosus (SIRIUS-SLE 1) | Skin and Connective Tissue Diseases, autoimmune disease, connective tissue disorder, immune system disorder, systemic lupus erythematosus | Active, not recruiting | Phase 3 | 2026-08-21 | NCT05639114 | |
| A Study to Investigate Efficacy, Safety, and Tolerability of Remibrutinib Compared With Placebo in Adults With CINDU Inadequately Controlled by H1-antihistamines | Chronic Disease, Disease Attributes, Hypersensitivity, Immediate, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Skin and Connective Tissue Diseases, chronic inducible urticaria, chronic urticaria, cold urticaria, immune system disorder, skin disorder, skin vascular disease, urticaria | Active, not recruiting | Phase 3 | 2026-08-20 | NCT05976243 | |
| A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy | Bacterial Infections and Mycoses, Infections, Skin and Connective Tissue Diseases, Suppuration, bacterial infectious disease, hidradenitis, hidradenitis suppurativa, skin disease caused by bacterial infection, skin disorder, skin disorder caused by infection, sweat gland disorder | Active, not recruiting | Phase 3 | 2026-08-20 | NCT05889182 | |
| A Randomized, Double-blind 2-arm, Followed by an Open-label 1-arm, NEPTUNUS Extension Study to Assess the Long-term Safety and Efficacy of Ianalumab in Patients With Sjogrens Syndrome. | Sjogren syndrome, Skin and Connective Tissue Diseases, Stomatognathic Diseases, Xerostomia, arthritic joint disease, arthropathy, autoimmune disease, connective tissue disorder, dry eye syndrome, eye disorder, immune system disorder, lacrimal apparatus disorder, mouth disorder, musculoskeletal system disorder, rheumatic disorder, rheumatoid arthritis, salivary gland disorder | Active, not recruiting | Phase 3 | 2026-08-19 | NCT05985915 | |
| Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS) (REMODEL-2) | Charcot-Marie-Tooth disease type 1F, Disease Attributes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Recurrence | Active, not recruiting | Phase 3 | 2026-08-18 | NCT05156281 | |
| A Study to Evaluate the Drug Levels, Efficacy and Safety of Deucravacitinib in Children and Adolescent Participants With Moderate to Severe Plaque Psoriasis | Skin Diseases, Papulosquamous, Skin and Connective Tissue Diseases, psoriasis, skin disorder | Recruiting | Phase 3 | 2026-08-18 | NCT04772079 | |
| Observational Study of Patients Receiving Dupixent® for Atopic Dermatitis (AD) | Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Hypersensitivity, Immediate, Skin Diseases, Eczematous, Skin and Connective Tissue Diseases, atopic eczema, dermatitis, hereditary disease, hereditary skin disorder, immune system disorder, skin disorder | Active, not recruiting | Not stated | 2026-08-06 | NCT03992417 | |
| An Extension Study for Treatment of Moderately to Severely Active Ulcerative Colitis | Digestive System Diseases, colitis, colonic disorder, digestive system disorder, gastroenteritis, inflammatory bowel disease, intestinal disorder, ulcerative colitis | Active, not recruiting | Phase 3 | 2026-07-09 | NCT03950232 | |
| Study to Continue Treatment With Darolutamide in Patients Who Have Been Participating in Previous Darolutamide Studies Supported by Bayer | cancer, neoplasm | Active, not recruiting | Phase 3 | 2026-07-07 | NCT04464226 | |
| Study Comparing Blinatumomab Alternating With Low-intensity Chemotherapy Versus Standard of Care Chemotherapy for Older Adults With Newly Diagnosed Philadelphia-negative B-cell Precursor Acute Lymphoblastic Leukemia | Newly Diagnosed Philadelphia (Ph)-Negative B-cell Precursor Acute Lymphoblastic Leukemia (ALL) | Active, not recruiting | Phase 3 | 2026-06-30 | NCT04994717 | |
| Pancreatic Cancer Screening Using the Enzeavour Assay in Japan | Digestive System Diseases, Digestive System Neoplasms, Neoplasms by Site, endocrine system disorder, malignant endocrine neoplasm, malignant pancreatic neoplasm, neoplasm, pancreas disorder, pancreatic neoplasm | Recruiting | Not applicable | 2026-06-26 | NCT07605819 | |
| Three-arm Study to Assess Efficacy and Safety of Ianalumab (VAY736) in Patients With Active Sjogren's Syndrome | Sjogren syndrome, Skin and Connective Tissue Diseases, Stomatognathic Diseases, Xerostomia, arthritic joint disease, arthropathy, autoimmune disease, connective tissue disorder, dry eye syndrome, eye disorder, immune system disorder, lacrimal apparatus disorder, mouth disorder, musculoskeletal system disorder, rheumatic disorder, rheumatoid arthritis, salivary gland disorder | Active, not recruiting | Phase 3 | 2026-06-17 | NCT05349214 |